A. Prechtl

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Randomized Adjuvant Chemotherapy Trial in High-Risk, Lymph Node-Negative Breast Cancer Patients Identified by Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor Type 1

F. Jänicke, A. Prechtl, Christoph Thomssen et al. · JNCI Journal of the National Cancer Institute · 2001 · 437 citations · Full text

Qualitative and Quantitative Assessment of Taste and Smell Changes in Patients Undergoing Chemotherapy for Breast Cancer or Gynecologic Malignancies

Silke Steinbach, Thomas Hummel, Christina Böhner et al. · Journal of Clinical Oncology · 2009 · 237 citations · Full text

Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.

F. Jänicke, L. Pache, Manfred Schmitt et al. · PubMed · 1994 · 120 citations

Tumor Biology, Breast Oncology, Oncology +15

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial

Marco Colleoni, Weixiu Luo, Per Karlsson et al. · The Lancet Oncology · 2017 · 120 citations

Breast Oncology, Medicine, Cancer Management +7